Dimensional Fund Advisors LP Lowers Stake in Alexion Pharmaceuticals, Inc. (ALXN)

Dimensional Fund Advisors LP lessened its holdings in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 1.0% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 360,706 shares of the biopharmaceutical company’s stock after selling 3,562 shares during the period. Dimensional Fund Advisors LP owned about 0.16% of Alexion Pharmaceuticals worth $50,599,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Citizens & Northern Corp lifted its position in shares of Alexion Pharmaceuticals by 10.0% in the 3rd quarter. Citizens & Northern Corp now owns 8,459 shares of the biopharmaceutical company’s stock worth $1,187,000 after purchasing an additional 768 shares during the period. Sii Investments Inc. WI purchased a new stake in shares of Alexion Pharmaceuticals in the 3rd quarter worth approximately $214,000. Schwab Charles Investment Management Inc. lifted its position in shares of Alexion Pharmaceuticals by 6.9% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 850,333 shares of the biopharmaceutical company’s stock worth $119,294,000 after purchasing an additional 54,761 shares during the period. Barings LLC lifted its position in shares of Alexion Pharmaceuticals by 92.8% in the 3rd quarter. Barings LLC now owns 5,860 shares of the biopharmaceutical company’s stock worth $822,000 after purchasing an additional 2,820 shares during the period. Finally, DSM Capital Partners LLC lifted its position in shares of Alexion Pharmaceuticals by 20.8% in the 3rd quarter. DSM Capital Partners LLC now owns 1,410,150 shares of the biopharmaceutical company’s stock worth $197,830,000 after purchasing an additional 243,001 shares during the period. 94.26% of the stock is owned by hedge funds and other institutional investors.

Alexion Pharmaceuticals, Inc. (ALXN) opened at $122.80 on Friday. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.51 and a current ratio of 2.96. Alexion Pharmaceuticals, Inc. has a 52 week low of $96.18 and a 52 week high of $149.34. The stock has a market cap of $27,460.00, a P/E ratio of 54.82, a price-to-earnings-growth ratio of 1.05 and a beta of 1.17.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.44 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.32 by $0.12. Alexion Pharmaceuticals had a net margin of 14.57% and a return on equity of 12.55%. The business had revenue of $859.00 million for the quarter, compared to analyst estimates of $864.34 million. During the same quarter in the prior year, the business posted $1.23 EPS. Alexion Pharmaceuticals’s revenue for the quarter was up 7.5% compared to the same quarter last year. equities research analysts expect that Alexion Pharmaceuticals, Inc. will post 4.82 earnings per share for the current fiscal year.

In other Alexion Pharmaceuticals news, CEO Ludwig Hantson sold 2,553 shares of the company’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $121.63, for a total transaction of $310,521.39. Following the transaction, the chief executive officer now owns 36,172 shares in the company, valued at approximately $4,399,600.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 4.35% of the company’s stock.

A number of research firms recently commented on ALXN. Leerink Swann reissued a “buy” rating and set a $182.00 target price on shares of Alexion Pharmaceuticals in a research report on Monday, September 25th. Zacks Investment Research cut shares of Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, October 2nd. Royal Bank of Canada began coverage on shares of Alexion Pharmaceuticals in a research report on Thursday, September 14th. They set an “outperform” rating and a $161.00 target price for the company. BMO Capital Markets reissued an “outperform” rating and set a $173.00 target price (up previously from $168.00) on shares of Alexion Pharmaceuticals in a research report on Wednesday, September 13th. Finally, Raymond James Financial reissued an “outperform” rating and set a $130.00 target price (down previously from $178.00) on shares of Alexion Pharmaceuticals in a research report on Thursday. They noted that the move was a valuation call. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and twenty have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $153.61.

ILLEGAL ACTIVITY WARNING: “Dimensional Fund Advisors LP Lowers Stake in Alexion Pharmaceuticals, Inc. (ALXN)” was published by Transcript Daily and is owned by of Transcript Daily. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this piece of content can be accessed at https://transcriptdaily.com/2018/01/06/dimensional-fund-advisors-lp-lowers-stake-in-alexion-pharmaceuticals-inc-alxn.html.

Alexion Pharmaceuticals Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply